Clinical Trial Update: Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing Thymoglobulin, Campath-1H, and Daclizumab in adult primary deceased donor renal transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Campath-1H (alemtuzumab)
• Daclizumab (daclizumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of Miami | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED